ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Injecting real-world data into every day clinical trials
Kathleen Mandziuk, VP Real World Solutions, offers insights into the importance of real-world data in clinical trials and how it can be used to inform trial recruitment.
The silent problem: Machine learning model failure - How to diagnose and fix ailing machine learning models
This article considers the current issues around the applicability of Machine Learning Models.
Welcome to the big leagues: How the US market is supercharging Irish businesses
Steve Cutler discusses how Irish companies, including ICON, intend to approach the US market, which brings a wealth of new opportunities and challenges.
Equipping our people leaders to drive an inclusive organisation
Mary O’Reilly and Nikki O’Hanlon discuss the vital role that people leaders play in driving diversity and inclusion within an organisation.
Defining quality tolerance limits and key risk indicators that detect risks in a timely manner
In this article, Gillian Pilbrow, along with multiple other SMEs from other organisations, discuss effective risk control through the earliest possible risk detection practices.
The decentralisation of clinical trials is a key catalyst for innovation in artificial intelligence
Michael Philips considers the impact of decentralised clinical trials on innovation in AI.
ICON: Where quality meets quantity
In this article, featuring commentary from CEO Steve Cutler, ICON’s key business moves in the last year are highlighted.
Business & Finance CEO 100 index 2022
Steve Cutler is featured in the first instalment of the annual CEO 100 index which recognises leading chief executives in Ireland.
PwC interview: Dr Steve Cutler, CEO of ICON plc
Participating in PWC's CEO Survey 2022, Dr Steve Cutler discusses the role of M&A in growth strategy.
How this top CEO helped Pfizer turbocharge the covid-19 vaccine
In an interview ith Investor's Business Daily, Steve Cutler discusses ICON's covid-19 efforts.